Literature DB >> 21301418

RNAi momentum fizzles as pharma shifts priorities.

Charles Schmidt.   

Abstract

Mesh：

Year:  2011        PMID： 21301418     DOI： 10.1038/nbt0211-93

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

Review 1.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

2.  A fabricated siRNA nanoparticle for ultra-long gene silencing in vivo.

Authors:  Seung Koo Lee; Ching-Hsuan Tung
Journal:  Adv Funct Mater       Date:  2013-07-26       Impact factor: 18.808

3.  Companies in footrace to deliver RNAi.

Authors:  Aaron Bouchie
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

4.  Hepatic RNA Interference: Delivery by Synthetic Vectors.

Authors:  Matthew Haynes; Leaf Huang
Journal:  Drug Deliv Transl Res       Date:  2014-02-01       Impact factor: 4.617

5.  Markets, venture investors and big pharma interest in RNAi soars.

Authors:  Aaron Bouchie
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

6.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

7.  Deoxyribozymes: new therapeutics to treat central nervous system disorders.

Authors:  Barbara Grimpe
Journal:  Front Mol Neurosci       Date:  2011-09-23       Impact factor: 5.639

8.  Antagonizing Sec62 function in intracellular Ca2+ homeostasis represents a novel therapeutic strategy for head and neck cancer.

Authors:  Sandrina Körner; Tillman Pick; Florian Bochen; Silke Wemmert; Christina Körbel; Michael D Menger; Adolfo Cavalié; Jan-Philipp Kühn; Bernhard Schick; Maximilian Linxweiler
Journal:  Front Physiol       Date:  2022-08-15       Impact factor: 4.755

9.  Antisense gene silencing: therapy for neurodegenerative disorders?

Authors:  Troels T Nielsen; Jørgen E Nielsen
Journal:  Genes (Basel)       Date:  2013-09-10       Impact factor: 4.096

10.  Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells.

Authors:  Maximilian Linxweiler; Stefan Schorr; Nico Schäuble; Martin Jung; Johannes Linxweiler; Frank Langer; Hans-Joachim Schäfers; Adolfo Cavalié; Richard Zimmermann; Markus Greiner
Journal:  BMC Cancer       Date:  2013-12-05       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.